A longitudinal study of natural antibody development to pneumococcal surface protein A families 1 and 2 in Papua New Guinean Highland children: a cohort study by Jacinta P. Francis et al.
PneumoniaFrancis et al. Pneumonia  (2016) 8:12 DOI 10.1186/s41479-016-0014-xRESEARCH Open AccessA longitudinal study of natural antibody
development to pneumococcal surface
protein A families 1 and 2 in Papua New
Guinean Highland children: a cohort study
Jacinta P. Francis1, Peter C. Richmond2,3, Audrey Michael1ˆ, Peter M. Siba1, Peter Jacoby4, Belinda J. Hales5,
Wayne R. Thomas5, Deborah Lehmann3, William S. Pomat1 and Anita H. J. van den Biggelaar3*Abstract
Background: Pneumococcal surface protein A (PspA), a conserved virulence factor essential for Streptococcus
pneumoniae attachment to upper respiratory tract (URT) epithelia, is a potential vaccine candidate for preventing
colonisation.
Methods: This cohort study was conducted in the Asaro Valley in the Eastern Highlands Province of Papua New
Guinea, of which Goroka town is the provincial capital. The children included in the analysis were participants in a
neonatal pneumococcal conjugate vaccine trial (ClinicalTrials.gov NCT00219401) that was conducted between 2005
and 2009. We investigated the development of anti-PspA antibodies in the first 18 months of life relative to URT
pneumococcal carriage in Papua New Guinean infants who experience one of the earliest and highest colonisation
rates in the world. Blood samples and nasopharyngeal swabs were collected from a cohort of 88 children at ages 3, 9,
and 18 months to quantify immunoglobulin G (IgG) levels to PspA families 1 and 2 using an enzyme-linked
immunosorbent assay and to determine URT carriage.
Results: Seventy-three per cent (64/88) of infants carried S. pneumoniae at age 3 months; 85 % (75/88) at 9 months,
and 83 % (73/88) at 18 months. PspA-IgG levels declined between ages 3 and 9 months (p < 0.001), then increased
between 9 and 18 months (p < 0.001). At age 3 months, pneumococcal carriers showed lower PspA1-IgG levels
(geometric mean concentration [GMC] 602 arbitrary units [AU]/ml, 95 % confidence interval [CI] 497–728) than non-
carriers (GMC 1058 AU/ml [95 % CI 732–1530]; p = 0.008), while at 9 months, PspA1- and PspA2-IgG levels were
significantly higher in carriers (PspA1: 186 AU/ml, 95 % CI 136–256; PspA2: 284 AU/ml, 95 % CI 192–421) than in
non-carriers (PspA1 87 AU/ml, 95 % CI 45–169; PspA2 74 AU/ml, 95 % CI 34–159) (PspA1: p = 0.037, PspA2: p = 0.003).
Conclusion: Our findings confirm that PspA is immunogenic and indicate that natural anti-PspA immune responses
are acquired through exposure and develop with age. PspA may be a useful candidate in an infant pneumococcal
vaccine to prevent early URT colonisation.
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Pneumonia is responsible for more than a million deaths
in young children every year and most of these deaths
occur in the developing world [1, 2]. In Papua New Guinea
(PNG), pneumonia is the most common cause of death in
children less than 5 years of age [3] and Streptococcus
pneumoniae is the most common cause of severe pneumo-
nia. Dense upper respiratory tract (URT) pneumococcal
carriage in PNG begins within weeks of birth (median age
of acquisition of 19 days [4]), is persistent throughout
childhood and is associated with increased risk of acquiring
pneumococcal diseases [5].
The currently available 10-valent (Synflorix™; GSK
Biologicals, Belgium) and 13-valent (Prevenar 13®; Pfizer,
USA) pneumococcal conjugate vaccines (PCVs) are
effective in reducing URT carriage and preventing inva-
sive disease caused by vaccine serotypes, but result to
some extent in replacement carriage with non-vaccine
serotypes, which in turn may lead to replacement dis-
ease, as was seen with the earlier marketed 7-valent
PCV (Prevenar®; Pfizer, USA) [6–10]. In particular, in
high-risk areas like PNG where the range of serotypes
causing pneumococcal disease has always been broader
than in areas of low endemicity, replacement by non-
vaccine virulent serotypes is more likely to occur. New
generation pneumococcal vaccines offering protection
against all invasive pneumococcal serotypes, which could
complement PCVs, would therefore be highly advanta-
geous. Several pneumococcal surface proteins with vac-
cine potential have been identified and are currently the
subject of research, including the pneumococcal surface
protein A (PspA). PspA is a surface protein that hinders
the activation and deposition processes of the host com-
plement system, particularly complement component C3
[11, 12], hence protecting the bacteria from undergoing
phagocytosis and clearance [13].
Animal models of carriage and infections have shown
that PspA is highly immunogenic and capable of gener-
ating protective antibodies against pneumococcal URT
carriage and infection [14–17]. The natural development
of immunity to PspA in humans has not been exten-
sively studied. Studies in children have been conducted
in countries with moderate and low endemicity, includ-
ing the Philippines, Australia, and Finland: these studies
indicated that there is development of serum PspA
family-specific immunoglobulin G (IgG) antibodies in
association with S. pneumoniae exposure through car-
riage or infection [18–21]. A study by Laine et al. [22] in
Kenya, a high-endemicity setting, demonstrated the
development of naturally acquired antibodies to PspA in
relation to age; however, this study did not look at
pneumococcal carriage. In a comprehensive study con-
ducted in mother–children pairs of refugees living on
the Thailand–Myanmar border, Turner and colleagues[23] analysed antibody responses to 27 pneumococcal
protein antigens, including PspA family 1 and PspA
family 2: no associations between pneumococcal carriage
and PspA-specific antibodies were found. Compared to
the Thailand–Myanmar refugees’ study [23] where the
median age of acquiring pneumococcal carriage was
45.5 days, young children in the highlands of PNG are
colonised at a median age of 19 days, and all are colonised
at least once by the age of 1 month [4]. Age at acquisition
may be an important factor determining immune out-
comes, considering that in the first few months of life the
immune system is undergoing rapid changes: in other
words, exposure to bacterial pathogens like S. pneumoniae
in the first weeks of life may result in a different immuno-
logical response than first exposure when a child is a few
months old and the immune system has further devel-
oped. It remains to be determined whether early and
dense pneumococcal colonisation of the URT, as experi-
enced by infants in high endemicity settings like PNG,
results in priming of protective immune responses, or
alternatively leads to immune tolerance and consequent
increased risk of persistent colonisation and disease.
PspA is a conserved protein that is expressed by virtu-
ally all S. pneumoniae strains; however, the protein
shows structural diversity between pneumococcal strains
and has been classified into 3 families based on sequence
variability of the N-terminal domain of PspA. Although
pneumococcal strains expressing family 1 or 2 PspA pro-
teins account for 98 % of clinical isolates, PspA-specific
IgG antibodies binding to this highly variable region are
family-dependent [24]. We have previously reported that
maternal-derived PspA1- but not PspA2-specific anti-
bodies were associated with a higher risk for pneumo-
coccal colonisation in Papua New Guinean infants [4],
indicating a possible difference in the frequency of
PspA1 versus PspA2 expressing pneumococcal strains
circulating in this population, or functional differences
between these family-specific antibodies.
The aims of this study were to examine the develop-
ment of naturally acquired IgG antibodies to PspA fam-
ilies 1 and 2 (PspA1 and PspA2) in the first 18 months
of life in a cohort of Papua New Guinean infants and to
determine the association between early pneumococcal
carriage and antibody responses to these proteins. We
hypothesise that, due to the high pneumococcal expos-
ure and early URT carriage experienced in our study
population, there will be high naturally acquired IgG
responses to the PspA proteins at a young age and that
these can protect against subsequent carriage.
Methods
Study design, setting, and population
This cohort study was conducted in the Asaro Valley in
the Eastern Highlands province of PNG, of which Goroka
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Medical Research (PNGIMR) headquarters, laboratories,
and small clinic are located next to Goroka General
Hospital, the only tertiary hospital in the province.
The children included in the analysis presented here were
participants in a neonatal PCV trial that was conducted
between 2005 and 2009. A detailed study protocol is pub-
lished in Phuanukoonnon et al. [25]. In summary, between
May 2005 and September 2007 pregnant women were re-
cruited at Goroka General Hospital antenatal clinic and in
villages located within an hour’s drive of Goroka town.
Inclusion criteria for enrolment of newborns were the
intention to remain in the study area for at least 2 years, a
birth weight >2000 g, no acute neonatal infection, and no
severe congenital abnormality. Children of mothers known
to be human immunodeficiency virus positive were
excluded. A total of 318 newborns were enrolled, of whom
104 were randomised to receive Prevenar® (PCV7, which
includes the serotypes 4, 6B, 9 V, 14, 18C, 19 F, and 23 F)
at birth, 1 and 2 months of age (neonatal group); 105 to
receive PCV7 at 1, 2, and 3 months of age (the infant
group); and 109 were randomised to the control group,
not receiving PCV7. All children received their recom-
mended childhood vaccines according to the Papua New
Guinean immunisation schedule including Bacillus
Calmette-Guérin vaccine at birth; oral polio vaccine at
birth, 1, 2, and 3 months; Hepatitis B vaccine at birth, 1,
and 3 months; a combined Haemophilus influenzae type
b, diphtheria, tetanus, whole cell pertussis vaccine at 1, 2,
and 3 months; and a measles vaccine at 6 and 9 months.
As part of the trial, at the age of 9 months, all children
received a dose of the 23-valent pneumococcal polysac-
charide vaccine (PPV) (Pneumovax23®; Merck & Co,
USA) containing serotypes 1, 2, 3, 4, 5, 6B, 7 F, 8, 9 N, 9 V,
10A, 11A, 12 F, 14, 15B, 17 F, 18C, 19 F, 19A, 20, 22 F,
23 F, and 33. Study infants were followed for 18 months
after birth, in which period there were 10 prescheduled
trial visits. In addition, village reporters conducted weekly
surveillance of study participants in rural areas throughout
the first year of life and then fortnightly to age 18 months.
A requirement for children to be included in the current
analysis on the development of IgG antibodies to PspA1
and PspA2 in relation to carriage was a complete set of
plasma samples and pernasal swabs at 3, 9, and 18 months
of age. Due to financial constraints, PspA-specific anti-
bodies were assessed for only 88 children. Selection was
based on the sequential ID numbers of children with
complete datasets: of these 88 children, 23 children had
been randomised to the neonatal PCV7 group, 38 to the
infant PCV7 group, and 27 to the control group.
Bacteriology of pernasal swabs
Standardised methodologies as described previously [26]
were used for collection, transportation, and storage ofthe pernasal swabs and subsequent culturing, identifica-
tion, and isolation of S. pneumoniae [26–28]. Briefly,
pernasal swabs were stored in 1 ml of skim milk-
glucose-glycerol broth (SMGGB) at -70 °C until further
processing at PNGIMR. After thawing and vortexing,
10 μl aliquots of the pernasal swabs in SMGGB were
streaked onto horse blood agar, chocolate agar, gentami-
cin blood agar (5 μg/ml), and bacitracin chocolate agar
(300 μg/ml). Plates were incubated overnight (18–24 h)
at 37 °C in 5 % CO2-enriched atmosphere. Presumptive
pneumococcal colonies were then cultured with an opto-
chin disc and confirmed to be S. pneumoniae based on
their susceptibility.
Detection and quantification of PspA-specific IgG using
an enzyme-linked immunosorbent assay (ELISA)
As described previously [4, 25, 29], venous blood sam-
ples were collected in sterile tubes containing 100
International Units of preservative-free heparin to allow
the collection and separation of peripheral mononuclear
cells and plasma. Samples were spun within 2 h of
collection for 10 min at 700 × g. Plasma samples were
aliquoted and stored at -20 °C until they were analysed.
PspA1 (family 1, clade 2) antigen was derived from
the recombinant Rx1AA1.0.302 protein, and PspA2
(family 2, clade 3) from PspA/V-24AA1.0.410. A detailed
description on the methodology for the expression and
purification of these recombinant antigens is described
in Francis et al. [4].
Minor changes were made to a previously established
ELISA for the detection and quantification of PspA-
specific IgG plasma antibodies [4], including using coating
concentrations of 1 μg/ml and 0.5 μg/ml for PspA1 and
PspA2, respectively, and using the new human anti-
pneumococcal capsule reference standard 007sp (National
Institute for Biological Standards and Control [NIBSC],
UK). The reference standard was serially diluted (two-
fold) using a starting dilution of 1/200 for PspA1 and
1/400 for PspA2. In addition, high and low quality
control plasma standards (taken from PNGIMR la-
boratory volunteers) were diluted at single dilutions of
1/400 and 1/1600, respectively, for both PspA anti-
gens, and test samples were serially diluted (two-fold)
using a starting dilution of 1/200.
Statistical analyses
Since PspA1- and PspA2-specific IgG antibody levels
were not normally distributed, analyses were performed
on log-transformed data. Paired t-tests were used to
investigate the changes in PspA1 and PspA2 antibody
concentrations between time points. Differences in geo-
metric mean concentrations (GMC) of PspA1- and
PspA2-specific IgG between pneumococcal carriers and
non-carriers at each time point were examined using
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assumption. To confirm these differences after account-
ing for potential confounding by the vaccine group, lin-
ear regression models were run with log concentration
as the dependent variable and vaccine group member-
ship was included as a covariate. Microsoft Excel version
2010 (Microsoft Corporation, USA) was used for data
management and generation of graphical presentations.
Statistical analyses were done using the statistical soft-
ware package Stata 11 (StataCorp LP, USA). Antibody
titres are expressed in arbitrary ELISA units (AU/ml).
Results
PspA1- and PspA2-specific antibody responses in relation
to age
Of the 88 children included in this analysis, 53 were
males and 35 were females; 23 were randomised to re-
ceive the neonatal PCV7 schedule, 38 received the infant
PCV7 schedule, and 27 received no PCV7. As illustrated
in Fig. 1a and b, PspA1- and PspA2-specific IgG re-
sponses decreased between 3 and 9 months of age
(PspA1, p < 0.001; PspA2, p < 0.001) and then increasedA
B
Fig. 1 Geometric mean concentrations (GMC) of IgG responses to
PspA1 (a) and PspA2 (b) in relation to age. Error bars indicate 95 %
confidence intervals of the GMC. PspA, pneumococcal surface
protein A; AU/ml, arbitrary ELISA units/mlbetween 9 and 18 months of age (PspA1, p < 0.001;
PspA2, p < 0.001).
PspA1- and PspA2-specific antibody responses in relation
to age and URT carriage
Pneumococcal carriage rates were 73, 85, and 83 % at 3,
9, and 18 months of age, respectively. All children
carried S. pneumoniae at least once by the age of
18 months. PspA family-specific IgG levels were com-
pared between pneumococcal carriers and non-carriers
at the corresponding time points. As illustrated in Fig. 2a,
at 3 months of age significantly lower PspA1-IgG levels
were found in the pneumococcal carrier group (GMC
602 AU/ml, 95 % confidence interval [CI] 497–728) than
in the non-carrier group (GMC 1058 AU/ml [95 % CI
732–1530]; p = 0.008). For PspA2-specific IgG responses
(Fig. 2b), differences were not significant at age
3 months although responses tended to be higher in
non-carriers (GMC 833 AU/ml, 95 % CI 565–1229)
than in pneumococcal carriers (GMC 606 AU/ml
[95 % CI 509–721]; p = 0.127). Conversely, at 9 months
of age significantly higher PspA1-IgG responses wereB
A
B
Fig. 2 Geometric mean concentrations (GMC) of IgG responses to
PspA1 (a) and PspA2 (b) in non-carrier (grey bars) and Streptococcus
pneumoniae carrier (black bars) infants at 3, 9, and 18 months of age.
Error bars indicate 95 % confidence intervals of the GMC.✩ p ≤ 0.05 is
considered a statistically significant difference. PspA, pneumococcal
surface protein A; AU/ml, arbitrary ELISA units/ml
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CI 136–256) than in non-carriers (GMC 87 AU/ml
[95 % CI 45–169]; p = 0.037). IgG responses against
PspA2 were also significantly higher in pneumococcal
carriers (GMC 284 AU/ml, 95 % CI 192–421) than in
non-carriers (GMC 74 AU/ml [95 % CI 34–159]; p = 0.003)
at 9 months. No significant differences in PspA1-specific
IgG responses were observed at 18 months of age between
children who carried S. pneumoniae (GMC 477 AU/ml,
95 % CI 342–664) or those who did not carry (GMC
618 AU/ml [95 % CI 296–1291]; p = 0.503); the same was
true for PspA2-specific IgG responses in the carriers (GMC
683 AU/ml, 95 % CI 491–949) and non-carriers (GMC
377 AU/ml [95 % CI 137–1041]; p = 0.250).
Linear regression models were run for each of the
above comparisons with adjustment for vaccine group.
Adjusted effect sizes were similar to unadjusted in all
cases and significance levels relative to p = 0.05 remained
unchanged (results not shown).
Discussion
To our knowledge this study is the first to examine the
natural development of circulating PspA family-specific
IgG antibodies in association with age and URT
pneumococcal carriage in a high-risk infant population.
There were high levels of antibodies at the age of
3 months (most likely due to the presence of maternally
derived antibodies) that waned by the age of 9 months.
Levels then rose between 9 and 18 months of age, most
likely as a result of natural pneumococcal exposure and
development of the child’s own immunity.
In a longitudinal study in the Philippines, Holmlund
et al. [19] examined natural antibody development to the
PspA family 1 protein and the effect of pneumococcal car-
riage on antibody development in infants aged 6 weeks to
10 months. Children were classified as carriers from the
time of first acquisition of S. pneumoniae. In this
moderate-risk setting, maternally derived PspA1 antibody
levels were found to decline to a low at age 20 weeks,
followed by a modest increase in circulating antibody to
PspA1, which tended to be higher in children who were
prior pneumococcal carriers. In our study in the high-risk
setting of PNG all children are colonised at least once by
the age of 1 month, often with multiple pneumococcal se-
rotypes; a prospective analysis as conducted in the Filipino
study [19] is therefore not feasible. The higher PspA-IgG
levels we found in non-carrier infants compared to the
carrier infants at 3 months of age suggest that maternally
derived antibodies may be protective and prevent or clear
URT carriage. These high anti-PspA IgG titres early in life
already show the potential activity of the protein if given
in the form of a maternal vaccination. The higher IgG re-
sponses to both PspA1 and PspA2 in the pneumococcal
carriers compared to non-carriers at 9 months of age(when maternal antibody has decayed) suggest that infants
at this age can generate a good immune response to high
levels of pneumococcal exposure. The high antibody titres
seen in the pneumococcal carriers in this study cohort at
9 months old may indicate immune priming, but by age
18 months there were no significant differences in antibody
titres against both PspA families between pneumococcal
carriers and non-carriers. The universal acquisition of the
pneumococcus by all Papua New Guinean infants by the
age of 18 months is likely to have stimulated the immune
response in all children, including the 17 % in whom the
pneumococcus was not detected at age 18 months. We
suggest that the observed association with pneumococcal
carriage as well as the anticipated difference in immune
maturation between individuals at 9 months of age can ex-
plain the larger variation in PspA-IgG concentrations that
we found at this age as compared to when children were
younger and responses were dominated by maternal anti-
bodies and when older when their history of exposure and
state of immune maturation may be less variable.
Papua New Guinean highland infants continue to ex-
perience a high prevalence of carriage, with 73 % of in-
fants already carrying S. pneumoniae in their noses by
3 months of age. While we looked at carriage status and
PspA antibody response levels in relation to vaccination
(because two-thirds of the children in the study had
received 3 doses of PCV7), no differences were found,
supporting earlier reports from PNG [30] and other
high-risk populations [31] that conjugate vaccination has
little effect on overall pneumococcal carriage in high-
risk populations.
This study has its limitations. Firstly, the sample size
of this study is relatively small and there were only 3
sampling points, which limits the power of the study.
Another limitation is that we did not assess bacterial
load by polymerase chain reaction (PCR). Instead of pre-
venting carriage, it is possible that antibodies acquired
to adhesins such as PspA reduce the density of pneumo-
coccal carriage and subsequent risk of invasive disease.
To date, financial constraints have precluded (semi)
quantitative PCR on any of the nasopharyngeal samples
collected as part of our trial. Finally, this study was not
designed to determine immune hyporesponsiveness fol-
lowing PPV. However, hyporesponsiveness is unlikely to
occur to a protein antigen following PPV vaccination.
Despite its limitations, this study does contribute to the
existing literature on naturally acquired antibody re-
sponses to PspA and their relationship to pneumococcal
carriage by providing novel data for children who, with a
median age of acquisition of 19 days, represent a popu-
lation with the earliest documented onset of pneumo-
coccal carriage. Yet, additional studies examining the
relationship between development of PspA antibody
responses, pneumococcal carriage (including load) and
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to better understand the immune potential of this
virulence antigen.
Conclusion
High and persistent URT S. pneumoniae carriage remains a
burden and predisposing factor for early acquisition of
pneumococcal diseases in Papua New Guinean children.
The development of naturally acquired IgG antibodies
against PspA increases with age as a result of active URT
carriage exposure. The protective role of naturally acquired
immunity to PspA against pneumococcal disease is not
clear. Administering a pneumococcal protein-based vaccine
containing multiple pneumococcal proteins including po-
tentially PspA1/2 as a complementary vaccine to currently
available PCV to offer universal serotype-independent pro-
tection against early pneumococcal carriage and disease,
may improve vaccine-induced prevention of pneumococcal
disease in high-risk populations.
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